Vial vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vial is a tech-enabled CRO that converts dermatology and ophthalmology clinics into research sites, handling regulatory administration, equipment provisioning, and patient recruitment; raised $77M Series B in 2022;
About
Vial is a clinical research organization (CRO) founded in 2020 by Simon Burns and Jason Wang and headquartered in San Francisco, California. The company has built a technology-enabled model for running clinical trials that differs from traditional CROs by directly partnering with clinical practices — particularly in dermatology and ophthalmology — and converting them into research sites. Vial handles the full operational burden: regulatory and IRB submissions, site staff training, clinical equipment provisioning, electronic data capture (EDC) setup, and patient recruitment and scheduling. This allows clinics with no prior research experience to participate in trials, dramatically expanding the pool of available sites and accelerating patient enrollment timelines.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.